

Sebastian Kufner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6267478/publications.pdf>

Version: 2024-02-01

55
papers

2,006
citations

471061

17
h-index

243296

44
g-index

58
all docs

58
docs citations

58
times ranked

2685
citing authors

#	ARTICLE	IF	CITATIONS
1	Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2019, 381, 1524-1534.	13.9	543
2	Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. <i>European Heart Journal</i> , 2009, 30, 2441-2449.	1.0	207
3	Randomized Trial of Paclitaxel- Versus Sirolimus-Eluting Stents for Treatment of Coronary Restenosis in Sirolimus-Eluting Stents. <i>Journal of the American College of Cardiology</i> , 2010, 55, 2710-2716.	1.2	192
4	Neointimal Modification With Scoring Balloon and Efficacy of Drug-Coated Balloon Therapy in Patients With Restenosis in Drug-Eluting Coronary Stents. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1332-1340.	1.1	98
5	Ten-Year Clinical Outcomes From a Trial of Three Limus-Eluting Stents With Different Polymer Coatings in Patients With Coronary Artery Disease. <i>Circulation</i> , 2019, 139, 325-333.	1.6	97
6	High-Sensitivity Troponin T and Mortality After Elective Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2259-2268.	1.2	88
7	Long-Term Efficacy and Safety of Paclitaxel-Eluting Balloon for the Treatment of Drug-Eluting Stent Restenosis. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 877-884.	1.1	85
8	Five-year outcomes from a trial of three limus-eluting stents with different polymer coatings in patients with coronary artery disease: final results from the ISAR-TEST 4 randomised trial. <i>EuroIntervention</i> , 2016, 11, 1372-137.	1.4	60
9	Randomized Trial of Polymer-Free Sirolimus- and Probucol-Eluting Stents Versus Durable Polymer Zotarolimus-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 784-792.	1.1	52
10	10-Year Outcomes From a Randomized Trial of Polymer-Free Versus Durable Polymer Drug-Eluting Coronary Stents. <i>Journal of the American College of Cardiology</i> , 2020, 76, 146-158.	1.2	49
11	Long-term outcome after sirolimus-eluting stents versus bare metal stents in patients with Diabetes mellitus: a patient-level meta-analysis of randomized trials. <i>Clinical Research in Cardiology</i> , 2011, 100, 561-570.	1.5	38
12	ISAR-PEBIS (Paclitaxel-Eluting Balloon Versus Conventional Balloon Angioplasty for In-Stent Restenosis) Trial. <i>Journal of the American College of Cardiology</i> , 2010, 55, 2710-2716.	1.6	38
13	Prognostic Impact of Periprocedural Myocardial Infarction in Patients Undergoing Elective Percutaneous Coronary Interventions. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e006752.	1.4	32
14	Covered stents for endovascular repair of iatrogenic injuries of iliac and femoral arteries. <i>Cardiovascular Revascularization Medicine</i> , 2015, 16, 156-162.	0.3	26
15	A meta-analysis of specifically designed randomized trials of sirolimus-eluting versus paclitaxel-eluting stents in diabetic patients with coronary artery disease. <i>American Heart Journal</i> , 2011, 162, 740-747.	1.2	24
16	Outcome after new generation single-layer polytetrafluoroethylene-covered stent implantation for the treatment of coronary artery perforation. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 912-920.	0.7	22
17	Long-Term Risk of Adverse Outcomes and New Malignancies in Patients Treated With Oral Sirolimus for Prevention of Restenosis. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 1142-1148.	1.1	20
18	ST-segment resolution after primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction. <i>Cardiology Journal</i> , 2012, 19, 61-69.	0.5	19

#	ARTICLE	IF	CITATIONS
19	Three-year efficacy and safety of new-versus early-generation drug-eluting stents for unprotected left main coronary artery disease insights from the ISAR-LEFT MAIN and ISAR-LEFT MAIN 2 trials. <i>Clinical Research in Cardiology</i> , 2016, 105, 575-584.	1.5	18
20	Five-year clinical outcomes of sirolimus-eluting versus paclitaxel-eluting stents in high-risk patients. <i>Catheterization and Cardiovascular Interventions</i> , 2011, 77, 494-501.	0.7	17
21	Sex differences in the outcome after percutaneous coronary intervention – A propensity matching analysis. <i>Cardiovascular Revascularization Medicine</i> , 2019, 20, 101-107.	0.3	17
22	Comparative prognostic value of postprocedural creatine kinase myocardial band and high-sensitivity troponin T in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 91, 215-223.	0.7	16
23	Comparative efficacy of two paclitaxel-coated balloons with different excipient coatings in patients with coronary in-stent restenosis. <i>International Journal of Cardiology</i> , 2018, 252, 57-62.	0.8	16
24	High-sensitivity cardiac troponin T and prognosis in patients with ST-segment elevation myocardial infarction. <i>Journal of Cardiology</i> , 2018, 72, 220-226.	0.8	15
25	Angiographic outcomes with biodegradable polymer and permanent polymer drug-eluting stents. <i>Catheterization and Cardiovascular Interventions</i> , 2011, 78, 161-166.	0.7	13
26	Second-generation versus first-generation sirolimus-eluting stents in diabetic patients with coronary artery disease: A randomized comparison in setting of ISAR-TEST 4 trial. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 82, E769-76.	0.7	13
27	Five-year clinical outcomes in patients with diabetes mellitus treated with polymer-free sirolimus- and probucol-eluting stents versus second-generation zotarolimus-eluting stents: a subgroup analysis of a randomized controlled trial. <i>Cardiovascular Diabetology</i> , 2016, 15, 124.	2.7	13
28	Long-Term Prognostic Impact of Restenosis of the Unprotected Left Main Coronary Artery Requiring Repeat Revascularization. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 2266-2274.	1.1	13
29	Sirolimus-eluting versus paclitaxel-eluting stents in diabetic and non-diabetic patients within sirolimus-eluting stent restenosis: Results from the ISAR-DESIRE 2 trial. <i>Cardiovascular Revascularization Medicine</i> , 2014, 15, 69-75.	0.3	12
30	Ticagrelor or Prasugrel for Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention. <i>JAMA Cardiology</i> , 2021, 6, 1121.	3.0	11
31	Impact of in-hospital stent thrombosis and cerebrovascular accidents on long-term prognosis after percutaneous coronary intervention. <i>American Heart Journal</i> , 2014, 168, 862-868.e1.	1.2	9
32	Relation of Ratio of Left Ventricular Ejection Fraction to Left Ventricular End-Diastolic Pressure to Long-Term Prognosis After ST-Segment Elevation Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 2019, 123, 199-205.	0.7	9
33	Early Aspirin Discontinuation After Coronary Stenting: A Systematic Review and Meta-Analysis. <i>Journal of the American Heart Association</i> , 2021, 10, e018304.	1.6	9
34	Prognostic value of glomerular function estimated by Cockcroft-Gault creatinine clearance, MDRD-4, CKD-EPI and European Kidney Function Consortium equations in patients with acute coronary syndromes. <i>Clinica Chimica Acta</i> , 2021, 523, 106-113.	0.5	9
35	Prognostic value of gamma-glutamyl transferase in patients with diabetes mellitus and coronary artery disease. <i>Clinical Biochemistry</i> , 2016, 49, 1127-1132.	0.8	8
36	Relationship of left ventricular end-diastolic pressure with extent of myocardial ischemia, myocardial salvage and long-term outcome in patients with ST-segment elevation myocardial infarction. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 901-909.	0.7	8

#	ARTICLE	IF	CITATIONS
37	Impact of perfusion restoration at epicardial and tissue levels on markers of myocardial necrosis and clinical outcome of patients with acute myocardial infarction. <i>EuroIntervention</i> , 2011, 7, 128-135.	1.4	8
38	Myocardial Perfusion Grade, Myocardial Salvage Indices and Long-Term Mortality in Patients With Acute Myocardial Infarction and Full Restoration of Epicardial Blood Flow After Primary Percutaneous Coronary Intervention. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2010, 63, 770-778.	0.4	7
39	Predicting factors for long-term survival in patients with out-of-hospital cardiac arrest – A propensity score-matched analysis. <i>PLoS ONE</i> , 2020, 15, e0218634.	1.1	7
40	Ten-year clinical outcomes of polymer-free versus durable polymer new-generation drug-eluting stent in patients with coronary artery disease with and without diabetes mellitus. <i>Clinical Research in Cardiology</i> , 2021, 110, 1586-1598.	1.5	7
41	Changes in high-sensitivity troponin after drug-coated balloon angioplasty for drug-eluting stent restenosis. <i>EuroIntervention</i> , 2017, 13, 962-969.	1.4	6
42	Target and non-target vessel related events at 10 years post percutaneous coronary intervention. <i>Clinical Research in Cardiology</i> , 2022, 111, 787-794.	1.5	6
43	Ten-Year Clinical Outcomes of Biodegradable Versus Durable Polymer New-Generation Drug-Eluting Stent in Patients With Coronary Artery Disease With and Without Diabetes Mellitus. <i>Journal of the American Heart Association</i> , 2021, 10, e020165.	1.6	5
44	Long-term clinical outcomes after drug eluting stent implantation with and without stent overlap. <i>Catheterization and Cardiovascular Interventions</i> , 2022, 99, 541-551.	0.7	5
45	Ten-year patterns of stent thrombosis after percutaneous coronary intervention with new- versus early-generation drug-eluting stents: insights from the DECADE cooperation. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2022, , .	0.4	5
46	Stent Optimization Using Optical Coherence Tomography and Its Prognostic Implications After Percutaneous Coronary Intervention. <i>Journal of the American Heart Association</i> , 2022, 11, e023493.	1.6	5
47	What Treatment Should We Dare in Patients With In-Stent Restenosis?. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 284-286.	1.1	4
48	Efficacy of drug-coated balloon angioplasty in early versus late occurring drug-eluting stent restenosis: A pooled analysis from the randomized ISAR DESIRE 3 and DESIRE 4 trials. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 1008-1015.	0.7	4
49	U-shaped association of central pulse pressure with long-term prognosis after ST-segment elevation myocardial infarction. <i>Heart and Vessels</i> , 2019, 34, 1104-1112.	0.5	3
50	Procedural and clinical performance of dual- versus single-catheter strategy for transradial coronary angiography: A meta-analysis of randomized trials. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 276-282.	0.7	2
51	A prospective trial of a novel low-dose paclitaxel-coated balloon therapy in patients with restenosis in drug-eluting coronary stents Intracoronary Stenting and Angiographic Results: Optimizing Treatment of Drug Eluting Stent In-stent REstenosis 3A (ISAR-DESIRE 3A). <i>Catheterization and Cardiovascular Interventions</i> , 2022, 99, 754-762.	0.7	2
52	Diagnosis and management of intramyocardial hematoma after coronary artery perforation. <i>Coronary Artery Disease</i> , 2016, 27, 327-330.	0.3	1
53	Diabetes mellitus and femoropopliteal in-stent restenosis. <i>Vasa - European Journal of Vascular Medicine</i> , 2022, , .	0.6	1
54	Drug-eluting stents for drug-eluting stent restenosis. <i>Coronary Artery Disease</i> , 2014, 25, 633-635.	0.3	0

#	ARTICLE	IF	CITATIONS
55	Ten-Year Clinical Outcomes in Patients With Acute Coronary Syndrome Treated With Biodegradable, Permanent-Polymer or Polymer-Free Drug-Eluting Stents.. Journal of Invasive Cardiology, 2022, 34, E266-E273.	0.4	0